Lv2
144 积分 2024-03-11 加入
Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic Potential
4天前
已完结
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
1个月前
已完结
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
1个月前
已完结
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
2个月前
已完结
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
2个月前
已完结
Outcomes in Patients with Obstructive Jaundice from Metastatic Colorectal Cancer and Implications for Management
3个月前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
3个月前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
3个月前
已完结
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
3个月前
已完结
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials
3个月前
已关闭
皖公网安备34019202002308
